#Immuno-Oncology (IO) Market share

[healthcaretechnologynews]

Is Merck’s Keytruda ahead of BMS Opdivo?

Both Keytruda and Opdivo are highly effective and commercially successful immunotherapies, yet Keytruda is at the forefront.

In newly diagnosed lung cancer, a commercial market opportunity that could reach $8 billion in sales annually, Merck’s Keytruda works and Bristol’s Opdivo does not.

With many failures in last 2-3 years for Nivolumab as monotherapy or as combination therapy, caused a fall flat, whereas consecutive accelerated approvals in past one year for Keytruda added to its market share and success.

Write to us at enquire@grgonline.com Learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

We really don’t always get to see a head-on confrontation like the Merck’s Keytruda (pembrolizumab) and BMS Opdivo (nivolumab). These two have always been so much hyped immunotherapies along with other PD-1/L1 inhibitors.

But these two used to steal the show many a times in most of the international major conferences. Even though Opdivo has been approved earlier than Keytruda, yet, we feel that Keytruda was a better player. Both drugs are highly effective and commercially successful immunotherapies. Both are even effective in treating patients with lung cancer that no longer responds to prior therapies.

However, in newly diagnosed lung cancer, a commercial market opportunity that could reach $8 billion in sales annually, Merck’s Keytruda works and Bristol’s Opdivo does not. Keytruda, first approved for advanced melanoma in 2014, is Merck’s most important growth driver. It has overtaken Bristol’s Opdivo as the industry’s immuno-oncology leader with sales expected to top $10 billion this year and $20 billion in 2024, according to IBES data. Kidney cancer is the latest proving ground for IO in combination with other drugs.

While treatments like Keytruda (pembrolizumab) and Opdivo (nivolumab) have proved startlingly effective for a minority of patients — depending on the tumor type — most don’t experience a significant benefit. In response, biopharma companies have leaned on combinations, but only with modest success.

Bristol-Myers’ combo of Opdivo and Yervoy has been one of those successes, with approvals in metastatic melanoma, certain types of colorectal cancer and, most recently, advanced renal cell carcinoma. The pairing has also underpinned a good part of Bristol-Myers’ commercial success in immuno-oncology. As Keytruda has become the immunotherapy of choice in lung cancer, more of Opdivo’s growth has come in melanoma and renal cell carcinoma, according to Bristol-Myers’ executives.

However, the combination is also hampered by Yervoy’s side-effect profile, which includes severe and fatal immune-related adverse reactions like enterocolitis and neuropathy. With many failures in last 2-3 years for Nivolumab as monotherapy or as combination therapy, might be due to the kind of patient segments they recruited in the respective trials, caused a fall flat. On the contrary, consecutive accelerated approvals in past one year for Keytruda added-in Merck’s Kitty have made it a better player than Opdivo.

Visit our website now: https://www.grgonline.com/

[karishmamulani]

Immuno Oncology (I-O) Market Evolving Opportunities, Covid-19 Impact, Strategies And Forecast

The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.

On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.

Buy Now : https://www.polarismarketresearch.com/checkouts/751

[deafeningmusicfury]

Immuno-Oncology Market Analysis by Essential Factors and Trends In Industry by 2025

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

Request for a sample copy of this research report @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample    

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.

On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market

Polaris Market research has segmented the Immuno-oncology market report on the basis of Treatment Approaches, novel targets, tumor types, and by region

 Immuno-Oncology Treatment Approach Outlook (Revenue, USD Million, 2015 – 2025)

Monoclonal Antibodies

Therapeutic Vaccines

Checkpoint Inhibitors

Cytokines

Immuno-Oncology Novel Target Outlook (Revenue, USD Million, 2015 – 2025)

IDO1i

LAG-3 CPI

Oncolytic virus

STING agonist

TLR agonist

HDACi

TIL

VEGFi

MEKi

TIGIT

CPI

GITR agonist

TGF-b trap

A2AR antagonist/CD73i

Immuno-Oncology Tumor Type Outlook (Revenue, USD Million, 2015 – 2025)

Melanoma

Non-Small Cell Lung Cancer

Renal Cell Carcinoma

Head & Neck Cancer

Bladder Cancer

Classical Hodgkin’s Lymphoma

Merkel Cell Carcinoma

Others

Immuno-Oncology Regional Outlook (Revenue, USD Million, 2015 – 2025)

U.S.

Canada

Germany

UK

China

India

Japan

Mexico

 Purchase This Report @: https://www.polarismarketresearch.com/checkouts/751

 About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us:

Polaris Market Research

Phone: 1–646–568–9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[researchtrendingmarket-blog]

Immuno-Oncology Market Strategic Insights and key Business Influencing Factors | Major Players – Huntsman International LLC, PPG Industries, W. R. Grace & Co.-Conn, Axalta Coating Systems.

Immuno-Oncology Market drives the Immuno-Oncology (IO) market. Due to adoption of unhealthy lifestyle and genetic modification/alteration also boost up the Immuno-Oncology (IO) market growth. However, increased advancement in the treatment of cancer and rise in population with immune system diseases worldwide will boost up the market. But, stringent FDA guidelines for the drug approval of new drug & adverse effect after the treatment may hamper the immuno-oncology (IO) market.

Immuno-oncology (IO) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of cancer related disorders worldwide and emerging markets are the factors responsible for the growth of this market.

 Get Sample Report at :

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-oncology-market

Competitive Analysis: Global Immuno-Oncology   Market

The major players covered in the immuno-oncology (IO) market are Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., Merck & Co., Inc., Regeneron Pharmaceuticals, GlaxoSmithKline Plc., Eli Lilly and Company, Fresenius Kabi AG, Pfizer Inc., AbbVie Inc., Genentech Inc., Sanofi, and AstraZeneca PLC., among others.

 Key Pointers Covered in the Global Immuno-Oncology Market Trends and Forecast to 2026

Global   Immuno-Oncology Market New Sales Volumes

Global   Immuno-Oncology  Market Replacement Sales Volumes

Global   Immuno-Oncology Market Installed Base

Global   Immuno-Oncology Market By Brands

Global   Immuno-Oncology Market Size

Global   Immuno-Oncology  Market Procedure Volumes

Global   Immuno-Oncology Market Product Price Analysis

Global   Immuno-Oncology Market Healthcare Outcomes

Global   Immuno-Oncology Market Cost of Care Analysis

Global   Immuno-Oncology Market Regulatory Framework and Changes

Global   Immuno-Oncology Market Prices and Reimbursement Analysis

Global   Immuno-Oncology Market Shares in Different Regions

Recent Developments for Global   Immuno-Oncology Market Competitors

Global   Immuno-Oncology Market Upcoming Applications

Global   Immuno-Oncology Market Innovators Study

Get Detailed TOC:

https://www.databridgemarketresearch.com/toc/?dbmr=global-immuno-oncology-market

 Immuno-Oncology (IO) Market Country Level Analysis

Global Immuno-Oncology (IO) is analysed and market size information is provided by country, type, target, indication, end-users and distribution channel as referenced above.

The countries covered in the immuno-oncology (IO) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America accounts the largest market share due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals. Europe is considered second largest market for immuno-oncology (IO) due to increased cancer & bone marrow surgeries. Asia-Pacific is expected to account for the largest market share over coming years due to increased government awareness programs and number of generic drugs.

Scope of the Immuno-Oncology   Market

Global Immuno-Oncology (IO) Market By Type (Immune Cell Therapy (CAR-T), Monoclonal Antibodies, Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Others), Targets (LAG-3, anti-CTLA-4, MAGE-A3, VEGF, HDAC, STING, TIM-3, TGF-Beta, OX40, Others), Indication (Malignant Tumors, Benign Tumors, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027.

Immuno-oncology (IO) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of cancer related disorders worldwide and emerging markets are the factors responsible for the growth of this market.

Growing cases of cancer and organ transplant drives the Immuno-Oncology (IO) market. Due to adoption of unhealthy lifestyle and genetic modification/alteration also boost up the Immuno-Oncology (IO) market growth. However, increased advancement in the treatment of cancer and rise in population with immune system diseases worldwide will boost up the market. But, stringent FDA guidelines for the drug approval of new drug & adverse effect after the treatment may hamper the immuno-oncology (IO) market.

Speak to Author :

https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-immuno-oncology-market

Key insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Report Here:

 Metabolic Syndrome Market 

Anxiety Disorder Market

[lazilysillyprince]

Nektar Therapeutics Offers A High-Potential But Controversial Pipeline

New Post has been published on http://helloall.us/2018/08/29/nektar-therapeutics-offers-a-high-potential-but-controversial-pipeline/

Nektar Therapeutics Offers A High-Potential But Controversial Pipeline

It has been a while since I updated my thoughts on Nektar Therapeutics (NKTR), and a lot has happened with this biotech over the past year, including a huge development deal with Bristol-Myers (BMY), mixed trial data at ASCO, and ongoing progress with additional compounds in the oncology pipeline. On top of all that, Nektar has a pain asset with potentially impressive upside, an exciting early-stage anti-inflammatory asset, and a significant amount of cash.

Nektar shares sold off hard after the disappointing ASCO results, but have since recovered 40%. At this price, I don’t necessarily think Nektar is seriously undervalued relative to the development risk. That’s a key caveat, though, as better clinical data on the NKTR-214 (or ‘214) melanoma program at the November SITC could restore some bullishness here and there is a lot of potential value in ‘214, NKTR-358, NKTR-262, and NKTR-255 that could be unlocked with future clinical successes.

A Year Later, ‘214 Is Still A Key Unknown

Clearly, the biggest driver for Nektar over the past year has been the rise and partial fall of expectations for ‘214, the company’s proprietary engineered IL-2 conjugate that could become a potent addition to immuno-oncology (or IO) combos. As I’ve written before, the IL-2 concept was validated long ago, but the use of it has been restricted by awful side-effects. While ‘214 showed rather unimpressive results as a monotherapy (something that does concern me…), the safety data have been very encouraging.

The big controversy now is still whether or not ‘214 really adds a meaningful benefit above and beyond PD-1 antibodies like Bristol’s Opdivo/nivolumab. Earlier data from the Phase II PIVOT study were encouraging, with a 64% ORR in frontline melanoma reported at the November SITC meeting (better, or at least on par with initial Opdivo+Yervoy results and Merck’s (MRK) Keytruda plus Incyte’s (INCY) epacadostat (a once-promising IDO inhibitor that failed rather spectacularly earlier this year)). Unfortunately, those results deteriorated at the ASCO update with a 52% ORR (though still showing a surprisingly strong ORR in PD-L1 negative patients).

Bulls argue that the incremental data presented at ASCO was too immature and that the new patients hadn’t been on therapy long enough. While there’s a reasonable argument to be made there, I think some bulls go a little too far in expecting a “deepening” response over time – though that has been the case with IO therapies in some cancers, melanoma studies have shown less of that (responses tend to come early or not at all).

Data in renal cell carcinoma (or RCC) have likewise been mixed, with ORR rising from 46% in November of 2017 to 71% early in 2018 to 54% at the ASCO presentation. Though more encouraging than the melanoma results, there have been other combos (including a levatinib/PD-1 antibody combo) that have done even better. Data from non-small cell lung cancer (or NSCLC) and bladder cancer have been encouraging, but the number of patients involved has been quite small, so the data are very preliminary at this point.

All told, I’m cautiously bullish on ‘214. I don’t see it being a mega-blockbuster like some bulls, and I do acknowledge the risk/possibility that it may go the route of Incyte’s epacadostat and show no meaningful benefit at all. After all, drugs that don’t show adequate efficacy as monotherapy don’t tend to suddenly become great in combos (synergy in oncology combos is rare .. but it can/does happen).

I do think, though, that if ‘214 can show similar efficacy as Yervoy in combination with Opdivo there is something here. Opdivo and Yervoy are a highly effective combo in cancers like melanoma, but the tolerability is awful, with 30% or more patients discontinuing because of severe adverse events. If ‘214 can add statistically significant efficacy to the Opdivo baseline but with a clean safety/tolerability profile, there should be worthwhile potential even if it’s just for those patients who can’t tolerate Opdivo+Yervoy combos.

The upside beyond that, though, is meaningful. While PD-1/PD-L1 antibodies are rightly hailed as major advances in cancer treatment, the complete response rates are low and there is still significant room for improvement in the number of overall responders. If ‘214 can increase the number of responders (and there’s evidence that the drug can “flip” some patients from PD-L1 negative status to PD-L1 positive) and/or the number of complete responses, that’s a very worthwhile drug with multiple billions of dollars in potential revenue across melanoma, RCC, NSCLC, bladder cancer, and other cancer types.

I’d also note that Nektar has put a lot of energy into making the most of this drug. Not only does the company have a major collaboration with Bristol-Myers (one that gives Nektar very strong economics and a lot of long-term strategic options), but the company has pursued other non-PD-1 partnerships with companies like Takeda (OTCPK:TKPYY) in hematology and Syndax (SNDX) in patients who’ve progressed while on PD-1 therapy.

… And There’s A Lot More Besides

Although ‘214 is the biggest value-driver for Nektar, it’s far from the only worthwhile pipeline opportunity.

Nektar’s pain drug ‘181 is under review at the FDA, and after surprisingly good Phase III data and positive abuse study results, I believe there’s more opportunity here than once thought. Capturing just mid-single-digit share of existing oxycodone and tramadol prescriptions should be enough to drive $1 billion in revenue, and I believe the lower abuse potential of ‘181 should make it an appealing option given the heightened awareness and concern over opioid abuse.

Netkar also has multiple other early-stage oncology assets in its pipeline, including a TLR agonist (‘262) and an IL-15-based therapeutic (‘255) superficially similar to ‘214 in some respects (it also induces NK cell and CD8+ cell proliferation and activation and enhances memory T-cell response). Nektar has begun studies of a ‘214+’262 combo in multiple cancer types (the REVEAL study) and should be underway with studies of ‘255 before too long. Although the TLR space is relatively crowded with experimental compounds, some of the pre-clinical (murine) work has been very encouraging and the proprietary combination of ‘214 and ‘262 could be powerful. Time will tell, though, and preliminary data should be available in 2019.

Nektar also has ‘358, its “anti-‘214” that has shown encouraging pre-clinical efficacy in activating regulatory T-cells and essentially calming the immune system, suggesting potential as a treatment for autoimmune diseases like lupus, Crohn’s, and rheumatoid arthritis. Nektar’s partner Lilly (LLY) is underway with dosing in its first study (lupus) and this is definitely a drug to watch.

The Opportunity

Nektar’s pipeline progress has certainly helped push concerns about its partnered marketed drugs to the back burner. AstraZeneca (AZN) continues to struggle to make real progress with Movantik, while Shire’s (SHPG) prospects for Adynovate aren’t looking nearly so promising giving recent competitive launches in hemophilia and potentially competitive late-stage clinical programs elsewhere. While these partnered programs still do figure into my valuation for Nektar, they’ve declined from once making up nearly half of the value (back in 2015, when ‘214 was barely even on investors’ radar) to less than 10% today.

‘214 is the biggest single value-driver for Nektar today, and I estimate a current value per share of about $28 on over $12 billion of addressable revenue opportunity with odds of success ranging from 30% to 50% across various indications. Given the scope and scale of the clinical program Bristol-Myers has agreed to, there’s certainly opportunity for more addressable revenue to come into that pool, as well as the opportunity for positive clinical data to de-risk those odds of success.

The very early-stage nature of ‘358, ‘262, and ‘255 significantly mitigates the current value of these drugs, but there is definitely material upside if or when the company presents positive clinical data that argue for higher odds of approval and/or a larger addressable market opportunity.

The Bottom Line

With ample cash (Nektar could still be sitting on $1 billion or more in cash when it turns free cash flow positive) and a deep pipeline, Nektar is definitely a credible biotech investment idea. Although I’m not as bullish as some on ‘214, my bias is positive given the mechanism of action and I hope future data read-outs strengthen that bias (seriously, who roots against a cancer drug working?). I just think that there are a lot of unknowns left in the pipeline and I believe in taking a conservative view on biotech valuation when there’s not a lot (or any) late-stage data. To that end, my fair value of Nektar is in the low $60’s right now and I’m not so interested in buying, but I freely admit that the real potential could be much higher if those clinical trials generate clean positive data.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

[udaycmi]

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[ameliepoorman-blog]

What Cannabis Actually Carries Out To Your Mind And Also Physical body.

Around this moment of year, final-year health care trainees are actually preparing their position listings for the residency suit which, for those who may not be familiar, are going to determine where they finish their residency instruction and just what field of medicine they will practice. Also, retail facilities as well as various other complements to primary care practices are certainly not geared up to provide constant and holistic maintain healthy and balanced clients or even sharp as well as precautionary maintain clients with complicated, severe, or sharp ailments. From blood circulation health to cancer cells to helping handle as well as treat genetic illness, nanotechnology has a lot of likely lifesaving treatments in medication. IPUs arised at first in the care for certain medical disorders, like breast cancer and shared replacement. Healthcare leaders and also plan creators have attempted numerous small repairs-- attacking fraud, decreasing errors, enforcing method guidelines, creating people better consumers," carrying out electronic filings-- however none have possessed a lot effect. Whether service providers like that or otherwise, healthcare is developing coming from a proficiency-based fine art to a data-driven scientific research, off free-lance medical professionals to hospital-employed medical doctors, coming from one-size-fits-all neighborhood medical facilities to extensive hospital networks coordinated around centers from superiority. Oncology drugs are actually considered the following outpost of lifestyle scientific researches with immuno-oncology (IO) medications at the forefront. EIT Wellness Germany GmbH, Heidelberg Startup Partners e.V. and also Heidelberg College coordinated the second Life Scientific research fulfills THAT" hackathon in Heidelberg. A cloud-based telemedicine system assists companies introduce their personal telehealth programs and expand their factors of access to care. Increasing our info foundation is actually critical to accomplishing these targets: Medco has records on 38 thousand individuals, which enable us to find out a lot even more about just how our drugs are recommended as well as utilized as well as, ultimately, exactly how efficient they reside in combating condition. Crunched through a nationwide shortage from primary care doctors, a lot of service providers are obliged to see several number of patients a week. But brand new proof altered the process: Armed forces wellness experts observed at an early stage that clients on whom tourniquets were actually utilized were most likely to survive their injuries. " You don't need to have a lots of things, but I probably experiment with different products more than other individuals do." Her Regimen Early morning 1. Hirsch purifies along with a basic facial cleanser, "often something you can find at the drug store" she says. If you adored this article therefore you would like to be given more info about measuretime.info generously visit our own web site. Leaders must make use of data to show how made a proposal adjustments could enhance productivity as well as patient results and also make use of vignettes concerning individuals' conquests and problems in order to get medical professionals thinking about exactly what sort of treatment creates all of them ashamed or pleased. An amazing brand new research finds clients report even worse adverse effects coming from inactive medicine when they assume it sets you back additional cash. While critical remarks of medication prices must pay attention to a patient's potential to manage therapy and also on profiteering through dishonest pharmaceutical firms, Biogen's rates decision signals a larger risk to the U.S. medical care unit: the collective cost of treatments for rare conditions may be actually difficult to birth. The principle has actually been attempted: In an agreement with the UK's National Hospital, the producer from the blood-cancer medication Velcade has to discount cash for the drug when that carries out not alter an individual's blood stream matter as planned. As an example, physicians and hospitals often condemn technology-driven item innovators for the healthcare body's high prices. PBMs are able to supply medicines to HMOs and sizable companies at low costs due to the fact that their higher volume of sales as well as their potential to move market portion enable all of them to work out small cost along with pharmaceutical providers. Today, the Clinic posts 14 various end results manuals" mentioning efficiency in handling a developing amount of problems (cancer, neurological health conditions, and also cardiac conditions, for instance). Structure Medicine is additionally partnering with Roche to develop brand-new cancer cells treatments. Over the past couple of years, the health care system, bolstered through pharmaceutical companies, swamped the US with opioid painkillers. And Congress might still revive a medical care costs that, through repealing Obamacare, would certainly reduce accessibility to substance addiction treatment for possibly countless folks fighting with medicine addiction.

[deafeningmusicfury]

Immuno-Oncology Market Size, Growth Opportunities, Trends by Manufacturers, Regions, Application & Forecast to 2026

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

Request for a sample copy of this research report @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample    

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.

On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market

Polaris Market research has segmented the Immuno-oncology market report on the basis of Treatment Approaches, novel targets, tumor types, and by region

 Immuno-Oncology Treatment Approach Outlook (Revenue, USD Million, 2015 – 2025)

Monoclonal Antibodies

Therapeutic Vaccines

Checkpoint Inhibitors

Cytokines

Immuno-Oncology Novel Target Outlook (Revenue, USD Million, 2015 – 2025)

IDO1i

LAG-3 CPI

Oncolytic virus

STING agonist

TLR agonist

HDACi

TIL

VEGFi

MEKi

TIGIT

CPI

GITR agonist

TGF-b trap

A2AR antagonist/CD73i

Immuno-Oncology Tumor Type Outlook (Revenue, USD Million, 2015 – 2025)

Melanoma

Non-Small Cell Lung Cancer

Renal Cell Carcinoma

Head & Neck Cancer

Bladder Cancer

Classical Hodgkin’s Lymphoma

Merkel Cell Carcinoma

Others

Immuno-Oncology Regional Outlook (Revenue, USD Million, 2015 – 2025)

 U.S.

 Canada

 Germany

 UK

 China

 India

 Japan

 Mexico

 Purchase This Report @: https://www.polarismarketresearch.com/checkouts/751

 About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us:

Polaris Market Research

Phone: 1–646–568–9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[udaycmi]

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com